[go: up one dir, main page]

PE20081683A1 - Nuevos derivados de sulfonamida - Google Patents

Nuevos derivados de sulfonamida

Info

Publication number
PE20081683A1
PE20081683A1 PE2008000100A PE2008000100A PE20081683A1 PE 20081683 A1 PE20081683 A1 PE 20081683A1 PE 2008000100 A PE2008000100 A PE 2008000100A PE 2008000100 A PE2008000100 A PE 2008000100A PE 20081683 A1 PE20081683 A1 PE 20081683A1
Authority
PE
Peru
Prior art keywords
nitro
halogen
phenyl
cyane
fluor
Prior art date
Application number
PE2008000100A
Other languages
English (en)
Inventor
David Banner
Harald Mauser
Rudolf E Minder
Hans P Wessel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081683A1 publication Critical patent/PE20081683A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES FENILO, HETEROARILO, HETEROCICLO, ENTRE OTROS; R1 Y R1' SON CADA UNO H, HALOGENO, NITRO, CIANO, ENTRE OTROS; R2, R2' Y R2'' SON CADA UNO H, HALOGENO, CIANO, NITRO, AMINO, ENTRE OTROS; X ES FENILENO SUSTITUIDO O NO POR 1-3 ELEGIDOS DE HALOGENO, CIANO, NITRO, AMINO, ENTRE OTROS; Y ES HETEROARILO SUSTITUIDO O NO. SON COMPUESTOS PREFERIDOS: (4-BROMO-2-TRIFLUOROMETIL-FENIL)-AMIDA DEL ACIDO 5-FLUOR-3-METIL-BENZO[b]TIOFENO-2 SULFONICO; [4-(2,6-DIFLUOR-PIRIDIN-4-IL)-2-TRIFLUOROMETIL-FENIL]-AMIDA DEL ACIDO 5-FLUOR-3-METIL-BENZO[b]TIOFENO-2- SULFONICO; ENTRE OTROS. REFERIDA ADEMAS A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE QUIMASA UTILES EN EL TRATAMIENTO DE ENFERMEDADES ALERGICAS, INFLAMATORIAS Y FIBROTICAS
PE2008000100A 2007-01-10 2008-01-09 Nuevos derivados de sulfonamida PE20081683A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07100337 2007-01-10

Publications (1)

Publication Number Publication Date
PE20081683A1 true PE20081683A1 (es) 2008-11-28

Family

ID=39271357

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000100A PE20081683A1 (es) 2007-01-10 2008-01-09 Nuevos derivados de sulfonamida

Country Status (15)

Country Link
US (1) US8158655B2 (es)
EP (1) EP2118062A1 (es)
JP (1) JP5208963B2 (es)
KR (1) KR101132577B1 (es)
CN (1) CN101578265B (es)
AR (1) AR064772A1 (es)
AU (1) AU2008204583A1 (es)
BR (1) BRPI0806542A2 (es)
CA (1) CA2674644A1 (es)
CL (1) CL2008000047A1 (es)
MX (1) MX2009007416A (es)
PE (1) PE20081683A1 (es)
TW (1) TW200836730A (es)
WO (1) WO2008084004A1 (es)
ZA (1) ZA200904802B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600748A (en) 2009-12-25 2014-06-27 Daiichi Sankyo Co Ltd Seven-membered ring compound and pharmaceutical use therefor
JP2013532688A (ja) 2010-07-26 2013-08-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃｙｐ１７阻害剤として有用なスルホンアミド化合物
GB201103419D0 (es) 2011-02-28 2011-04-13 Univ Aberdeen
US9371307B2 (en) 2011-09-12 2016-06-21 The Johns Hopkins University Serine protease inhibitors
IL316000A (en) * 2022-04-05 2024-11-01 Socpra Sciences Sant? Et Humaines S E C Chymase inhibitors for selective resolution of thrombus in thrombotic or thromboembolic disorders
CN117024616B (zh) * 2023-07-10 2025-01-21 张琦 一种褐藻多糖衍生物纳米胶束的制备及其应用
CN117342987B (zh) * 2023-10-12 2025-11-18 济南诺博汀精细化工有限公司 一种布美他尼的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE654017A (es) * 1963-04-04 1965-04-06
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
AR008245A1 (es) 1996-06-21 1999-12-29 Glaxo Group Ltd Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
CN1245400C (zh) * 2000-09-18 2006-03-15 东亚荣养株式会社 N－取代苯并噻唑磺胺衍生物
US7071220B2 (en) 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
DE60333351D1 (de) * 2002-03-15 2010-08-26 Toa Eiyo Ltd N-substituiertes benzothiophensulfonamidderivat
JP2006505559A (ja) 2002-10-18 2006-02-16 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６受容体親和性を持つ４−ピペラジニルベンゼンスルホニルインドール
CA2571058A1 (en) 2004-06-22 2006-01-05 Schering Corporation Cannabinoid receptor ligands
KR20070041762A (ko) * 2004-07-28 2007-04-19 글락소 그룹 리미티드 위장관 장애의 치료에 유용한 피페라진 유도체
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
TW200808695A (en) 2006-06-08 2008-02-16 Amgen Inc Benzamide derivatives and uses related thereto
WO2008026046A1 (en) * 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
KR101312993B1 (ko) 2006-10-28 2013-11-25 엔비보 파마슈티칼즈, 인코퍼레이티드 히스톤 데아세틸라아제의 억제제
US8071623B2 (en) 2007-01-10 2011-12-06 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
DE602007011670D1 (de) 2007-01-10 2011-02-10 Irm Llc Verbindungen und zusammensetzungen als kanal-aktivierende proteasehemmer

Also Published As

Publication number Publication date
ZA200904802B (en) 2013-01-30
CN101578265B (zh) 2013-05-08
US20080167348A1 (en) 2008-07-10
US8158655B2 (en) 2012-04-17
KR101132577B1 (ko) 2012-04-05
CA2674644A1 (en) 2008-07-17
CN101578265A (zh) 2009-11-11
MX2009007416A (es) 2009-07-17
JP5208963B2 (ja) 2013-06-12
AR064772A1 (es) 2009-04-22
BRPI0806542A2 (pt) 2014-04-22
KR20090090375A (ko) 2009-08-25
TW200836730A (en) 2008-09-16
EP2118062A1 (en) 2009-11-18
RU2009130452A (ru) 2011-02-20
WO2008084004A1 (en) 2008-07-17
AU2008204583A1 (en) 2008-07-17
CL2008000047A1 (es) 2008-07-18
JP2010515699A (ja) 2010-05-13

Similar Documents

Publication Publication Date Title
PE20081683A1 (es) Nuevos derivados de sulfonamida
NO20081464L (no) 1-heterocyklusulfonyl, 2-aminometyl, 5-(hetero-)aryl subsidiert 1-H-pyrrol-derivater som syresekresjonsinhibitorer
PE20080538A1 (es) Derivado heterociclico fusionado y su uso
PE20080077A1 (es) Derivados de sulfonilfenilo como antagonistas del receptor de il-8
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
ATE496043T1 (de) 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
PE20060361A1 (es) Compuestos heterociclicos como inhibidores de la cinesina mitotica
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
DE602005023343D1 (de) Pyrimidinderivate als gpcr-agonisten
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20121148A1 (es) Compuestos heterociclicos y usos de los mismos
PE20120403A1 (es) Aril-piridinas como inhibidoras de sintasa de aldosterona
PE20120655A1 (es) Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map)
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
CO5611147A2 (es) Derivados de nicotinamida utiles como inhibidores p38
PE20091096A1 (es) Compuestos organicos
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
NO20051694L (no) Heterosykliske forbindelser
PE20081532A1 (es) Compuestos novedosos
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina
PE20021002A1 (es) Compuestos heterociclicos condensados

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed